FCGR1A and neoplasm: From a therapeutic perspective, targeting of stromal FAP with monoclocal antibodies can be effective, particularly when combined with tumor targeting approaches against the prostate tumor antigen tumor-associated calcium signal transducer 2 (TROP2) using engineered natural killer NK-92 cells expressing CD64 [23].